Bad News/Good News For Cholesterol: Another Strike Against HDL, But Support For Stricter LDL Targets
Executive Summary
A large genetic analysis published in the Lancet suggests that drugs that raise HDL may not reduce cardiovascular risk, creating more bad news for a field still reeling from the failure of Roche’s dalcetrapib. But another study calls for much wider use of LDL-lowering drugs, even in patients with low cardiovascular risk.
You may also be interested in...
NewAmsterdam Is Behind Another Try At CETP Inhibition, With Menarini’s Help
Years after failures by Merck, Lilly, Pfizer and Roche, NewAmsterdam hopes to bring a CETP inhibitor to market to lower cholesterol, and signs on with Menarini to lead commercial efforts in Europe.
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.
Preparing For Battle: PCSK9 Sponsors Stake Their Ground
The strong efficacy and sound safety data coming out of the Phase III programs presented at ACC have all eyes on the commercial opportunity for the PCSK9 inhibitor class. Ongoing outcomes trials and market impact of new cholesterol guidelines sparked discussion, and leading sponsors Amgen and Sanofi/Regeneron talked about the potential populations and differences in the devices and dosing of evolocumab and alirocumab.